Maduro U.S. Drug Trafficking Trial Set for June 2027 as Immunity Defense Looms 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Paramount-Warner Bros. Merger Delayed Until 2027 Amid Antitrust Lawsuit 
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge 
Gold Prices Rise as Fed Rate Hike Bets Ease 
US Dollar Near Two-Month Low as Markets Await Inflation Data 
US Yen Intervention Unlikely to Deliver Lasting Recovery, Yardeni Says 
S&P 500, Nasdaq Futures Rise as Iran Risks and CPI Loom 
New Mexico Sues DOJ Over Unredacted Jeffrey Epstein Files Amid Ongoing Investigation 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
U.S. Unseals Charges Against Five Alleged CJNG Leaders, Raises Reward for New Cartel Chief 
Bristol Myers Squibb has sued AstraZeneca for its antibody-based cancer treatment Imjudo, which it says infringes its patents for its drug Yervoy
According to Bristol Myer, Imjudo fights cancer in the same way as Yervoy.
Bristol Myers has previously sued AstraZeneca for patent infringement over the latter’s other cancer drug, Imfinzi.
AstraZeneca said it is aware of the complaint and will respond to it "at the appropriate time."
The FDA has also approved the immunotherapy Yervoy for the treatment of kidney, lung, colorectal, and other cancers. The FDA initially approved Yervoy in 2011 to treat melanoma.
In 2021, Bristol Myers sold over $2 billion worth of Yervoy.
AstraZeneca’s Imjudo was given FDA approval last year to be used in conjunction with Imfinzi to treat liver and lung cancer.
In the second lawsuit, Bristol Myers claimed that AstraZeneca had violated two patents on the use of antibodies to treat cancer and strengthen a patient's immune system.
Bristol Myers insists that AstraZeneca was aware of the patents, being on notice due to licensing discussions and the Imfinzi lawsuit.
The lawsuit seeks an unspecified amount of money for damages.
